Close

Amyris (AMRS) Prices $300M Public Offering (Secondary and Primary) of Common Stock at $15.75/sh

April 9, 2021 6:10 AM EDT

Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced the pricing of an underwritten public offering of an aggregate of 19,047,619 shares of its common stock at a public offering price of $15.75 per share, which consists of a secondary offering of 11,390,797 shares to be sold, in the aggregate, by DSM International B.V. and affiliates of Vivo Capital LLC (the selling stockholders) and 7,656,822 shares to be sold by Amyris.

Amyris will not receive any proceeds from the sale of shares in the secondary offering by the selling stockholders. The gross proceeds from the offering to Amyris, before deducting the underwriting discount and commissions and estimated offering expenses, and assuming no exercise of the underwriters' option to purchase additional shares, are expected to be approximately $120.6 million.

The selling stockholders and Amyris have granted the underwriters a 30-day option to purchase up to an additional 2,857,142 shares of Amyris common stock at the public offering price, less underwriting discounts and commissions. Of this 30-day option, up to 1,708,619 shares may be sold by the selling stockholders and up to 1,148,523 shares may be sold by Amyris. The offering is expected to close on or about April 13, 2021, subject to the satisfaction of customary closing conditions.

J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as the joint bookrunning managers for the offering.

The public offering is being made pursuant to an automatic shelf registration statement on Form S-3 that was filed by Amyris with the U.S. Securities and Exchange Commission (the "SEC") on April 7, 2021, and automatically became effective upon filing.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Equity Offerings

Related Entities

JPMorgan, Cowen & Co, S3